Financial Data and Key Metrics Changes - Net sales for Q3 2026 were $13.4 million, an increase of 7% or approximately $900,000 compared to the previous year, outperforming broader trends in a restrained consumer spending environment [4][9] - Gross margin remained strong at 87%, with a slight improvement in the take rate to 6.2% from 6.17% in the same period last year [5][10] - Adjusted EBITDA increased by 54% to $6.5 million compared to $4.3 million in Q3 2025, representing 49% of net sales [8][9] - Net income before discontinued operations was $1,465,000, a significant improvement from a loss of $21,177,000 in the same period last year, translating to earnings per share of $0.01 versus a loss of $0.18 [7][9] Business Line Data and Key Metrics Changes - Firearm unit sales increased over 8% from the previous quarter, while Adjusted NICS decreased by 3.7%, resulting in an increased share of Adjusted NICS by 56 basis points [9] - Gross merchandise value (GMV) rose to nearly $216 million, with a growth of 6.4% [9][10] - The non-firearms category experienced a decline, partially offsetting the increase in firearm GMV [9] Market Data and Key Metrics Changes - The company noted that the tax holiday in Florida contributed to increased sales, but it was not a large driver of overall performance [29] - The removal of the NFA tax is expected to drive renewed interest in firearms, contributing positively to sales [31][60] Company Strategy and Development Direction - The company is focused on improving user experience on GunBroker.com and has announced a strategic partnership with Master FFL to streamline the transfer process for regulated products [10][43] - The near-term objective is to achieve a $25 million Adjusted EBITDA run rate before sales growth over the next 12 months [13] - The company is committed to disciplined capital allocation to support long-term shareholder value, including a stock repurchase program [14][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about continued cost optimization and targeted investments to enhance user experience, which is expected to drive traffic and revenue [15] - Legal costs are anticipated to impact cash generation in the short term, but a larger percentage of cash from operations is expected to be retained as legal matters are resolved [11][12] - The company is exploring opportunities for reasonably priced debt financing, which could support various capital allocation strategies [50][52] Other Important Information - Operating expenses were significantly reduced by approximately $22 million year-over-year, with a notable decline in litigation-related costs [5][11] - The company has a strong cash position of nearly $69.9 million, including $500,000 of interest income [10] Q&A Session Summary Question: What is driving the good performance in firearm sales versus NICS? - Management highlighted the focus on buyer experience and streamlined processes as key factors driving growth, along with strong performance in used firearms [17][18] Question: What is the status of universal payments implementation? - Management indicated that about 30% of transactions are not done through credit cards, and universal payments could significantly enhance the buyer experience and increase GMV [20][21] Question: What are the expectations for legal fees and professional fees in the coming quarters? - Management noted that legal costs are variable and may not trend consistently, but efforts are ongoing to resolve legal issues quickly [24][25] Question: How did the tax holiday in Florida impact sales? - Management confirmed that while sales were up, the tax holiday was not a major driver, with both new and used firearms contributing to the increase [29][30] Question: What are the expectations for cash generation and capital allocation? - Management is always looking for capital allocation strategies and is open to exploring reasonably priced debt financing opportunities [50][52]

Financial Data and Key Metrics Changes - Revenue for Q3 2026 increased by 18% to $41.8 million from $35.4 million in the same quarter last year, driven by higher shipment volumes to major export markets, including the U.S. and a new customer in Korea [10] - Gross profit rose by 31% to $7 million from $5.4 million year-over-year, with gross profit margin improving to 16.9% from 15.2% due to a favorable product mix and economies of scale [10][11] - Operating income nearly tripled to $1.9 million from $708,000 in the same quarter last year, while net income increased to $1.2 million or $0.09 per diluted share from $6,000 or $0.00 per diluted share [11] - Cash and restricted cash totaled $13.2 million, with net working capital at $36.4 million as of December 31, 2025 [12] Business Line Data and Key Metrics Changes - The company is expanding its manufacturing capacity by acquiring a 184,000 sq ft facility in Amman, Jordan, with an investment of approximately $5 million for renovations and equipment [4][5] - The new facility is expected to increase manufacturing capacity by at least 40%, supporting growing demand from existing customers and new business opportunities [5][9] - The company is also developing additional facilities in rural towns, which are expected to add 5%-10% to total production capacity [9] Market Data and Key Metrics Changes - The company has seen increased order projections from major customers for calendar year 2026, with facilities fully booked through July [9] - Jordan is being recognized as a preferred manufacturing hub, with many global brands diversifying their manufacturing footprint to the region [6][9] Company Strategy and Development Direction - The long-term strategy aims to more than double current production capacities in the next five years while diversifying the customer base and product mix [10] - The company is focused on cost control and operational efficiency as it implements its expansion strategy [13] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future prospects, expecting Q4 2026 revenue to increase by 23%-26% year-over-year, with gross margin targets of 14%-16% [13] - The company is closely monitoring the political situation in the region and has contingency plans in place to ensure stable operations [41][45] Other Important Information - The board of directors approved a regular quarterly dividend of $0.05 per share, payable on February 20, 2026 [12] - The effective tax rate for the quarter was lower at 24%, with projections for future rates between 25%-30% as the company engages in tax planning [62][64] Q&A Session Summary Question: How will the expansions impact the income statement and balance sheet? - The $5 million for renovations and equipment will be financed by the Housing Bank, showing up as long-term debt on the balance sheet [16][18] Question: Can you provide details on the new facilities being developed? - The new satellite factories will help create job opportunities in rural areas and are expected to improve overall efficiency [21][22] Question: How quickly can the new capacity be ramped up? - Renovations are expected to be completed by the end of 2026, with a ramp-up period of 1-2 years to fully utilize the new capacity [30] Question: What is the outlook for gross margins going forward? - Margins may decrease as the company returns to more complex styles, but efficiency improvements and new technology will help control costs [33] Question: What is the contingency plan regarding political instability in the region? - The company is monitoring the situation closely and has been assured that Jordan will remain stable, with efficient operations at key ports [41][45] Question: What are the plans for cash on the balance sheet? - The company is utilizing cash for growth and working capital, with plans to consider other financing alternatives once a comfortable level is reached [46][47] Question: How is the health of the largest customers affecting pricing? - There is pricing pressure due to tariffs, but the company maintains strong relationships with customers and is seen as a reliable manufacturer [50][51]

Financial Data and Key Metrics Changes - The company reported total sales of $943 million for Q1 fiscal 2026, reflecting a 0.6% increase year-over-year, with comparable sales flat compared to the previous year [4][19] - Adjusted diluted earnings per share increased by 12% to $0.48, exceeding guidance [4][21] - Gross margins improved to 51.3%, up 50 basis points year-over-year, primarily due to higher product margins [20][21] - Cash flow from operations was strong at $93 million, with free cash flow at $57 million [5][23] Business Line Data and Key Metrics Changes - In the Sally segment, net sales increased by 1.2% to $532 million, with comparable sales essentially flat [21][22] - The core color category in the Sally segment grew by 8%, while care declined by 6% [22] - The BSG segment saw net sales decrease by 0.2%, with comparable sales also flat [22][23] - E-commerce sales for Sally grew by 20% to $50 million, representing 9% of segment net sales [22] Market Data and Key Metrics Changes - The Sally U.S. and Canada business delivered positive comparable sales growth of 1.3% for the quarter [5] - Global e-commerce sales increased by 11% to $111 million, accounting for 12% of total net sales [20] - The company exited most lower-margin full-service operations in Europe, which is expected to result in a modest sales headwind of approximately $10 million for the full year [6] Company Strategy and Development Direction - The company is focused on four key growth drivers: understanding and activating the customer, unlocking digital value, differentiating with product assortment and innovation, and accelerating new growth pathways [9][14] - The "Save While You Skip the Salon" campaign is aimed at customer acquisition and retention, particularly among millennials and Gen Z [9][10] - The company is expanding its fragrance category, with plans to have fragrance in 2,000 stores by the end of the second quarter [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the customer base despite macroeconomic challenges, noting a rebound in performance following government shutdowns [5][30] - The company anticipates a strong Q2, with guidance for consolidated net sales between $895 million and $905 million, reflecting a favorable comparison to the previous year's weaker quarter [25][44] - Management remains cautious but optimistic about the second half of fiscal 2026, expecting continued momentum from new initiatives and customer engagement strategies [58] Other Important Information - The company is on track to capture approximately $45 million in benefits from its Fuel for Growth program in fiscal 2026, contributing to cumulative savings of $120 million by year-end [18][21] - The company ended the quarter with $157 million in cash and cash equivalents, with no outstanding borrowings [23] Q&A Session Summary Question: Comparison of BSG and Sally customers and trends - Management noted that BSG customers are more value-focused, with a cautious approach to spending on add-on services, while Sally customers showed resilience and positive growth in color sales [29][30] Question: Promotional environment and expectations - Management indicated that promotional levels were slightly up year-over-year, but gross margins remained strong, and they do not expect a highly promotional period in Q2 [38][39] Question: Customer demographics for fragrance - Initially, fragrance customers are primarily existing customers, with plans to expand marketing efforts as the product line grows [40] Question: Q2 outlook context - Management highlighted that Q2 is expected to benefit from easier comparisons to last year's weak quarter, with positive momentum in both segments [42][44] Question: Category growth expectations - Management remains optimistic about color category growth, while care has been softer; new categories like skin and spa are seen as significant opportunities [52]

Financial Data and Key Metrics Changes - The cash position at December 31 was $131.7 million with no debt, and the company utilized $7.1 million in operating activities during the quarter, indicating a cash runway of more than three years at the current utilization rate [8][9] - Research and development expenses for the quarter were $4.7 million, down from $10.4 million in the same quarter last year, while general and administrative expenses decreased to $2.1 million from $3.1 million [8][9] - The net loss for the quarter was reported at $5.7 million, or $0.06 per share [9] Business Line Data and Key Metrics Changes - The decrease in operating expenses was primarily due to the completion of a large manufacturing campaign for blarcamesine and a reduction in clinical trial activities following the completion of the Anavex 3-71 phase II study in schizophrenia [9] Market Data and Key Metrics Changes - The company is participating in the ACCESS-AD initiative, which aims to accelerate the adoption of innovative diagnostic and therapeutic approaches for Alzheimer's disease across Europe, funded by the European Commission [4][51] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, particularly the lead candidate oral blarcamesine for early Alzheimer's disease, and is working with regulatory agencies in Europe and the U.S. to develop this treatment option [3][4] - Anavex plans to provide updates on regulatory and clinical trial developments for blarcamesine in other indications, including Parkinson's disease and fragile X syndrome [5][6] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the potential of blarcamesine to improve the lives of patients with neurological disorders and emphasized the importance of scalable treatment options with oral administration [10][60] - The company acknowledged the challenges posed by regulatory feedback but remains committed to addressing these through data resubmissions and ongoing clinical trials [4][44] Other Important Information - The company is preparing for a confirmatory phase trial if approved under the Conditional Marketing Authorization (CMA) pathway, which will involve real-world cohorts of paying patients [49][51] - Anavex is also planning to present new scientific findings at upcoming conferences, which may further support its clinical claims [6] Q&A Session Summary Question: Can you provide additional information regarding the rapporteur and co-rapporteur for the re-examination of the CHMP opinion on blarcamesine? - The rapporteurs will be selected from the 27 EU countries [15] Question: What is the timeline for the re-examination process? - The re-examination process is expected to last for the first half of the year, involving a 60 + 60-day period for responses and reviews [16] Question: What additional information will be included in the resubmission to the EMA? - The resubmission will include data from the AD-004 study, A-Clear study population, and correlations of clinical efficacy with brain atrophy reduction [24] Question: Are there any ongoing trials currently? - The only ongoing trials are compassionate use programs for Rett Syndrome and Alzheimer's Disease, with plans for studies in Parkinson's Disease and Fragile X Syndrome [28] Question: How will the ACCESS-AD program involve blarcamesine? - The program will include a placebo-controlled trial of blarcamesine targeting early Alzheimer's patients, focusing on biomarkers and efficacy [51][52]

Financial Data and Key Metrics Changes - In Q4 2025, the company achieved GAAP net income of $34 million and operating cash flow of $80 million, marking a significant turnaround from a loss of $238 million in the previous year [6][27] - For the full year 2025, revenues reached $1.3 billion, up 26% year-over-year, with adjusted EBITDA of $371 million, up 76% year-over-year, and GAAP net income of $81 million, a $483 million improvement compared to 2024 [6][21] - The fourth quarter revenue was $335 million, with a 29% adjusted EBITDA margin, and FRLPC (Fee Revenue Less Production Costs) was $131 million, up 12% year-over-year [22][24] Business Line Data and Key Metrics Changes - Personal loans accounted for approximately 65% of total network volume, growing 10% year-over-year, while auto and point-of-sale (POS) represented 19% and 16% of quarterly network volume, respectively [22] - The company reported a network volume of $2.7 billion for Q4, up 3% year-over-year, with full-year network volume at $10.5 billion, up 9% [22][23] Market Data and Key Metrics Changes - The company noted a proactive tightening of production in certain areas to mitigate higher variability of credit outcomes, which resulted in a reduction of approximately $100 million-$150 million in fourth quarter volume without impacting profitability targets [23][24] - The company has diversified its funding sources, creating almost $3 billion of revolving capacity through ABS structures across point-of-sale and personal loans [12][30] Company Strategy and Development Direction - The company is focused on sustainable, profitable growth, emphasizing prudent risk management over short-term gains, and aims to build a B2B2C platform that integrates deeply into the U.S. financial ecosystem [8][13] - Future growth is expected to come from onboarding new partners and deepening existing relationships, with a robust pipeline of new partner launches anticipated [9][14] Management's Comments on Operating Environment and Future Outlook - Management highlighted that while consumer performance remains strong, there is increased uncertainty in the market, prompting a cautious approach to credit exposure [18][66] - The guidance for 2026 reflects a cautious outlook, with expected GAAP net income ranging from $100 million to $150 million, assuming current market conditions persist [35][61] Other Important Information - The company has established long-term agreements with major partners, enhancing business stability and alignment [10][14] - The company reported a significant improvement in operating leverage, with core operating expenses declining to 36% of FRLPC, a 13-point improvement year-over-year [26] Q&A Session Summary Question: Can you elaborate on the decision to move away from variable outcomes? - Management emphasized the importance of prudent risk management over short-term growth, noting that they are not reliant on marketing spend to generate volume, allowing for more flexibility in decision-making [37][40] Question: How is the funding environment looking for 2026? - Management indicated strong demand for their products and noted that the funding environment is becoming more disciplined, which is beneficial for the company [58][59] Question: What specific actions were taken to pull back on risk? - The company primarily pulled back across the entire portfolio, with a focus on personal and auto loans due to the growth seen in POS [73]

Financial Data and Key Metrics Changes - The company generated record combined fee-related earnings (FRE) and spread-related earnings (SRE) of $5.9 billion, driving adjusted net income of $5.2 billion, which is up 14% year-over-year, equating to $8.38 per share [4][6] - FRE for the year was $2.5 billion, reflecting a 23% increase year-over-year, while SRE was $3.4 billion, normalized to a 9% increase year-over-year [6][34] - The company achieved record inflows of $228 billion, marking the third consecutive record year for both Athene and Asset Management [6][7] Business Line Data and Key Metrics Changes - The origination volume crossed the $300 billion mark, with a robust consistent spread of 350 basis points over treasuries [6][7] - In the individual market, inflows exceeded $18 billion, with nine strategies raising over $500 million annually [9] - Athene's net invested assets grew by 18% year-over-year to $292 billion, with record inflows of $83 billion driven by retail and funding agreements [31][36] Market Data and Key Metrics Changes - The company reported that all buckets of credit increased by 8%-12%, with hybrid value up 16% for the year [8] - The global wealth business raised $18 billion, up nearly 50% year-over-year, indicating strong demand across multiple client types and geographies [30] - The institutional business had a record year, with $15 billion in new mandates from third-party insurance [28] Company Strategy and Development Direction - The company is transitioning from serving one market to six markets, including individuals, insurance, and traditional asset managers, requiring different products and investments in technology [8][9] - The focus is on a total portfolio approach, which opens up debt and equity buckets to private assets, enhancing competition with public assets [10][11] - The company aims for 20%+ FRE growth in 2026, with a strong emphasis on maintaining quality alongside scale [11][40] Management's Comments on Operating Environment and Future Outlook - Management highlighted the increasing demand for retirement income and the global retirement crisis, expecting approximately $85 billion of inflows in 2026 [11][12] - The outlook for SRE growth remains durable, with a reaffirmed expectation of 10% growth on average through 2029 [12][41] - Management emphasized the importance of a principal mindset in investing, focusing on long-term ownership rather than short-term market trends [13][14] Other Important Information - The company plans to increase the annual per-share dividend by 10% from $2.04 to $2.25 starting in Q1 2026, reflecting a commitment to returning capital to shareholders [40] - The company has returned approximately $1.5 billion to shareholders through dividends and repurchases during the year [39] Q&A Session Summary Question: Implications of the ARI transaction on SRE - Management indicated that the ARI transaction helps de-risk the year and supports the goal of 10% SRE growth, but it should not be assumed to be additive [46][50] Question: Dynamics in the non-traded BDC space and ADS - Management noted that the philosophy of portfolio construction in ADS has resonated well, with net new assets increasing over $5 billion last year despite market turbulence [52][53] Question: Interaction with LPs regarding private allocations - Management expects increased dispersion among managers and a shift in institutional allocations towards private assets, driven by public market volatility [57][60] Question: Origination opportunities and margin profile - Management highlighted the globalization of origination strategies and the focus on quality and scale, with expectations for continued growth in FRE margins [73][75]

Pagaya Technologies (NasdaqCM:PGY) Q4 2025 Earnings call February 09, 2026 08:30 AM ET Company ParticipantsEvangelos Perros - CFOGal Krubiner - CEOHal Goetsch - Senior Managing Director and Head of FinTech and FinancialsJosh Fagen - Head of Investor Relations and COO of FinanceKyle Joseph - Managing DirectorRayna Kumar - Head of Fintech Equity ResearchSanjiv Das - PresidentConference Call ParticipantsDavid Scharf - Managing Director and Equity Research AnalystJohn Hecht - Managing Director and Senior Equity ...

Financial Data and Key Metrics Changes - For Q1 of fiscal 2026, total revenue was $120.9 million, a slight increase of $1 million or 0.8% from $119.9 million in Q1 of fiscal 2025, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue [12][19] - DSA revenue increased to $48 million from $42.8 million, representing a year-over-year growth of 12%, with discovery pharmacology service and surgical services contributing significantly [5][12] - RMS revenue decreased by $4.1 million or 5.4% to $72.9 million, primarily due to lower NHP volumes sold [14][15] - The overall operating loss increased to $16.3 million from $15.5 million, driven by a higher RMS operating loss [16][19] - Consolidated net loss totaled $28.4 million or $0.83 loss per diluted share, compared to a net loss of $27.6 million or $1.02 loss per diluted share in the prior year [18][19] Business Line Data and Key Metrics Changes - DSA business saw strong growth with net new awards of $53.6 million, a 27% increase over Q1 of fiscal 2025, and a trailing twelve-month increase of 34% [13] - DSA margins improved, with non-GAAP operating income for the DSA segment at $8.2 million or 6.8% of total revenue, up from $7.1 million or 5.9% [17] - RMS segment's non-GAAP operating income decreased to $7.2 million or 5.9% of total revenue, down from $9.4 million or 7.9% due to lower NHP volume sales [18] Market Data and Key Metrics Changes - The book-to-bill ratio for DSA in Q1 of fiscal 2026 was 1.16 to 1, with a trailing twelve-month book-to-bill of 1.08 to 1 [14] - DSA backlog increased to $145.4 million at December 31, 2025, compared to $138.2 million at September 30, 2025 [14] Company Strategy and Development Direction - The company is focused on improving revenue and margins in the DSA business while reducing costs and diversifying revenue sources in the RMS business [10] - The company is enhancing its NAM strategy to support FDA guidance and industry expectations for innovation, with recent collaborations aimed at integrating advanced machine learning tools [10][50] - The company is committed to optimizing its operational footprint and product portfolio while maintaining client satisfaction [11] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the DSA business's momentum and the ongoing site optimization and cost reduction initiatives in the RMS business [9] - The company is navigating macroeconomic factors affecting the RMS business and remains committed to refinancing its debt and improving its balance sheet [9][20] - Management anticipates continued improvement in margins and revenue growth in the DSA segment as pricing stabilizes and operational efficiencies are realized [26][31] Other Important Information - The company engaged Perella Weinberg Partners for financial advisory services to explore debt refinancing alternatives [9] - Capital expenditures for Q1 of 2026 were $5.2 million, with expectations to keep annual CapEx below 4% of revenue [21][22] Q&A Session Summary Question: Can you provide more details on profitability and adjusted EBITDA trends? - Management noted that seasonality impacts the first quarter, and increased operating expenses were observed, particularly in cost of goods sold [25][26] Question: What is the outlook for DSA awards and growth? - Management highlighted that DSA growth is supported by improved customer relationships and scientific strength, with expectations for continued positive trends [28][30] Question: Can you explain the recent decline in RMS revenue and operating leverage? - Management indicated that reduced NHP volumes overshadowed operating leverage benefits, but cost reductions from facility closures are expected to yield improvements in future quarters [38][40] Question: How are recent weather conditions impacting operations and costs? - Management confirmed that weather impacts shipping and operations, but the overall cost impact is not significant [51][52]

Financial Data and Key Metrics Changes - Total revenue increased by 7% year-over-year, with an adjusted growth of 9% when accounting for a $2 million accelerated product revenue from the previous year [6][23] - Service revenue grew by 11% year-over-year, now representing 80% of total revenue, up from 77% in the prior year [6][22] - Adjusted EBITDA increased by 26% year-over-year to $25.7 million, with margins expanding by 4% to 23% [7][24] - Net debt to Adjusted EBITDA improved to 2.7 times, with expectations to decline to around 2.4 times by year-end [7][25] Business Line Data and Key Metrics Changes - The company is focusing on high-margin recurring revenue, with services revenue growth indicating a strong shift towards this model [22] - The integration of the Fleet Complete acquisition is reflected in the financials, impacting service gross margins by over 6% due to amortization [22] Market Data and Key Metrics Changes - The company secured a significant contract with the South African government, expected to generate substantial recurring SaaS and services revenue over a multi-year term [8][9] - The AI video pipeline grew by 71% sequentially, indicating strong demand for advanced safety and compliance solutions [11] Company Strategy and Development Direction - The company aims for a Q4 exit run rate for FY26 of 10% total revenue growth and over 10% growth in recurring revenue, positioning itself for accelerated growth in FY27 [4][5] - The Unity platform is central to the company's strategy, providing integrated solutions that enhance operational efficiency and safety across various industries [15][18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the improving business environment, citing successful navigation through previous challenges such as tariffs [41] - The company is optimistic about achieving a 15% ARR growth for FY27, bolstered by the recent large contract win [32][33] Other Important Information - The company is maintaining disciplined operational execution while investing in growth initiatives, with a focus on optimizing costs and enhancing service delivery [24][59] - The management highlighted the importance of AI as an enabler for the industry, enhancing data utilization and operational decision-making [35][36] Q&A Session Summary Question: Growth mix and contribution of new logos versus upsell - Management indicated that 65%-70% of business comes from existing customers, with 30% from new logos, including the South African government contract [31] Question: Business environment comparison to six months ago - Management noted that the business environment is improving, with increased enterprise engagement and repeat business due to tangible ROI from solutions [40][42] Question: Update on the South African contract's revenue potential - While specific financial details could not be disclosed, management suggested that the contract aligns with existing ARPU and margin expectations, indicating significant future revenue potential [43] Question: Competitive landscape for the South African contract - Management confirmed that the contract was highly competitive, with a focus on robust capabilities and partnerships, particularly with MTN [75] Question: Cost structure related to the South African contract - Management clarified that initial investments would focus on people, processes, and systems to support the contract, with a strategy to optimize existing resources for future growth [56][59]

Financial Data and Key Metrics Changes - For Q1 of fiscal 2026, total revenue was $120.9 million, a slight increase of $1 million or 0.8% from $119.9 million in Q1 of fiscal 2025, primarily driven by increased DSA revenue and partially offset by decreased RMS revenue [12][19] - DSA revenue increased to $48 million from $42.8 million, reflecting a year-over-year growth of 12%, with discovery pharmacology service and surgical services contributing significantly [5][12] - RMS revenue for Q1 of fiscal 2026 was $72.9 million, a decrease of $4.1 million or 5.4% compared to the prior year, primarily due to lower NHP volumes sold [14][15] - The overall operating loss increased to $16.3 million from $15.5 million in the prior year, driven by an increase in RMS operating loss [16][19] - Consolidated net loss totaled $28.4 million or $0.83 loss per diluted share, compared to a net loss of $27.6 million or $1.02 loss per diluted share in Q1 of fiscal 2025 [18][19] Business Line Data and Key Metrics Changes - DSA business saw strong growth with net new awards of $53.6 million, a 27% increase over Q1 of fiscal 2025, and a 34% year-over-year increase for the trailing twelve-month period [13][19] - DSA margins improved, with non-GAAP operating income for the DSA segment at $8.2 million or 6.8% of total revenue, compared to $7.1 million or 5.9% in the prior year [17] - RMS segment reported non-GAAP operating income of $7.2 million or 5.9% of total revenue, down from $9.4 million or 7.9% in the prior year, primarily due to lower NHP volume sales [18] Market Data and Key Metrics Changes - The book-to-bill ratio for DSA in Q1 of fiscal 2026 was 1.16 to 1, with a trailing twelve-month book-to-bill ratio of 1.08 to 1, indicating a healthy order intake relative to revenue [6][14] - DSA backlog increased to $145.4 million at December 31, 2025, compared to $138.2 million at September 30, 2025, and $130.4 million at December 31, 2024 [14] Company Strategy and Development Direction - The company is focused on improving revenue and margins in the DSA business while reducing costs and diversifying revenue sources in the RMS business [10][11] - The company is enhancing its NAM strategy to support FDA guidance and industry expectations for innovation, with recent collaborations aimed at integrating advanced machine learning tools [10][50] - The site optimization plan is expected to improve margins in future periods, with the current phase set to complete by Q3 of fiscal 2026 [7][9] Management Comments on Operating Environment and Future Outlook - Management expressed optimism about the DSA business's momentum and the ongoing site optimization and cost reduction initiatives in the RMS business [9][10] - The company is navigating macroeconomic factors affecting the RMS business and remains committed to refinancing its debt and improving its balance sheet [9][20] - Management noted that while the first quarter typically experiences seasonality challenges, they expect to see improvements in margins and revenue in the latter half of the fiscal year [26][28] Other Important Information - The company has received a waiver for non-compliance with financial covenant ratios under its credit agreement for Q1 of fiscal 2026 [9] - Capital expenditures in Q1 of 2026 were $5.2 million, with expectations for annual CapEx to remain below 4% of revenue [21][22] Q&A Session Summary Question: Can you provide more details on profitability and adjusted EBITDA trends? - Management acknowledged that margins in RMS impacted adjusted EBITDA, with some operational expenses higher than expected, and indicated that seasonality will likely follow previous patterns [25][26] Question: What is driving the positive trend in DSA awards? - Management attributed the growth in DSA awards to improved customer relationships, increased sales force efforts, and scientific strengths within the company [29][31] Question: What is the outlook for RMS operating leverage? - Management indicated that reduced NHP volumes overshadowed operating leverage benefits, but cost reductions from facility closures will contribute positively in future quarters [40][42] Question: How much was NHP volume down year-over-year? - Management reported that NHP volumes were down approximately 25% year-over-year [44][45] Question: Can you elaborate on new relationships in the NAM space? - Management highlighted ongoing R&D efforts and collaborations aimed at innovation, which are expected to drive incremental revenues [49][50]